GSK entered a collaboration with LTZ Therapeutics to develop up to four myeloid cell engager candidates using LTZ’s immune‑engager platform, paying $50 million upfront. The partnership targets both hematologic and solid tumors and joins a wave of Big Pharma investments in novel engager modalities that recruit innate immune cells. GSK gains access to LTZ’s platform to expand its immuno‑oncology portfolio while LTZ secures capital and industry validation to advance discovery and preclinical assets toward IND‑enabling work.